P 13

Drug Profile

P 13

Alternative Names: P-13; Peptide P-13

Latest Information Update: 20 Jul 2016

Price : $50

At a glance

  • Originator Unknown
  • Developer 13therapeutics
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Toll like receptor 2 antagonists; Toll-like receptor 4 antagonists; Toll-like receptor 9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Noise-induced hearing loss; Otitis media

Most Recent Events

  • 20 Jul 2016 Preclinical trials in Otitis media in USA (unspecified route)
  • 20 Jul 2016 Preclinical trials in Noise-induced hearing loss in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top